JP2020518556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518556A5 JP2020518556A5 JP2019555219A JP2019555219A JP2020518556A5 JP 2020518556 A5 JP2020518556 A5 JP 2020518556A5 JP 2019555219 A JP2019555219 A JP 2019555219A JP 2019555219 A JP2019555219 A JP 2019555219A JP 2020518556 A5 JP2020518556 A5 JP 2020518556A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- amino acid
- disorders
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 208000030159 metabolic disease Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 230000001771 impaired effect Effects 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 208000029751 Amino acid metabolism disease Diseases 0.000 claims 3
- 208000017701 Endocrine disease Diseases 0.000 claims 3
- 208000002720 Malnutrition Diseases 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000002124 endocrine Effects 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 102000005720 Glutathione transferase Human genes 0.000 claims 2
- 108010070675 Glutathione transferase Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 108091006269 SLC5A2 Proteins 0.000 claims 2
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 235000000824 malnutrition Nutrition 0.000 claims 2
- 230000001071 malnutrition Effects 0.000 claims 2
- 229950004994 meglitinide Drugs 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 2
- 208000023184 Body fat disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010021000 Hypoglycaemic coma Diseases 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- 201000010538 Lactose Intolerance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 230000037354 amino acid metabolism Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000020450 carbohydrate metabolism disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 210000003372 endocrine gland Anatomy 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000017745 inborn carbohydrate metabolic disease Diseases 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 230000006372 lipid accumulation Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000009996 pancreatic endocrine effect Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 150000004032 porphyrins Chemical class 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000022558 protein metabolic process Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004144 purine metabolism Effects 0.000 claims 1
- 230000004147 pyrimidine metabolism Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000004137 sphingolipid metabolism Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023051477A JP2023082076A (ja) | 2017-05-04 | 2023-03-28 | 糖尿病の処置のためのペプチド |
| JP2025037548A JP2025090703A (ja) | 2017-05-04 | 2025-03-10 | 糖尿病の処置のためのペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17169500.0 | 2017-05-04 | ||
| EP17169500 | 2017-05-04 | ||
| PCT/EP2018/061547 WO2018202870A1 (en) | 2017-05-04 | 2018-05-04 | Peptides for treatment of diabetes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051477A Division JP2023082076A (ja) | 2017-05-04 | 2023-03-28 | 糖尿病の処置のためのペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518556A JP2020518556A (ja) | 2020-06-25 |
| JP2020518556A5 true JP2020518556A5 (enExample) | 2021-06-17 |
Family
ID=58671461
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555219A Pending JP2020518556A (ja) | 2017-05-04 | 2018-05-04 | 糖尿病の処置のためのペプチド |
| JP2023051477A Ceased JP2023082076A (ja) | 2017-05-04 | 2023-03-28 | 糖尿病の処置のためのペプチド |
| JP2025037548A Pending JP2025090703A (ja) | 2017-05-04 | 2025-03-10 | 糖尿病の処置のためのペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051477A Ceased JP2023082076A (ja) | 2017-05-04 | 2023-03-28 | 糖尿病の処置のためのペプチド |
| JP2025037548A Pending JP2025090703A (ja) | 2017-05-04 | 2025-03-10 | 糖尿病の処置のためのペプチド |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10815283B2 (enExample) |
| EP (1) | EP3618845B1 (enExample) |
| JP (3) | JP2020518556A (enExample) |
| KR (1) | KR102700014B1 (enExample) |
| CN (1) | CN110545834B (enExample) |
| AU (1) | AU2018262805B2 (enExample) |
| BR (1) | BR112019021886A2 (enExample) |
| CA (1) | CA3061935A1 (enExample) |
| DK (1) | DK3618845T3 (enExample) |
| EA (1) | EA201992562A1 (enExample) |
| ES (1) | ES2857749T3 (enExample) |
| IL (1) | IL270199B2 (enExample) |
| MX (1) | MX2019013096A (enExample) |
| PL (1) | PL3618845T3 (enExample) |
| SG (1) | SG11201908513RA (enExample) |
| WO (1) | WO2018202870A1 (enExample) |
| ZA (1) | ZA201905891B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202104276YA (en) * | 2018-11-07 | 2021-05-28 | Follicum Ab | Peptide fragments for treatment of diabetes |
| EP3958835B1 (en) * | 2019-04-24 | 2023-05-24 | Follicum AB | Topical formulation |
| KR102816261B1 (ko) * | 2022-03-24 | 2025-06-05 | (주)케어젠 | 항당뇨 활성을 갖는 펩타이드 복합체 및 이의 용도 |
| WO2023218095A1 (en) * | 2022-05-13 | 2023-11-16 | Coegin Pharma Ab | Agents for stimulating tissue regeneration |
| KR20250010632A (ko) * | 2022-05-13 | 2025-01-21 | 코에긴 파르마 아베 | 혈관신생 유도 제제 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996008513A1 (en) * | 1994-09-16 | 1996-03-21 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same |
| WO1999015904A1 (en) | 1997-09-26 | 1999-04-01 | University Of Washington | Methods and compositions for diagnosing renal pathologies |
| US6551990B2 (en) | 1998-12-07 | 2003-04-22 | University Of Washington | Methods of inhibiting ectopic calcification |
| AU4256901A (en) * | 2000-03-23 | 2001-10-03 | Glaxo Group Limited | Method of screening for inhibitors of osteopontin |
| CA2411346A1 (en) | 2000-06-13 | 2001-12-20 | Children's Medical Center Corporation | Biosynthetic oncolytic molecules and uses therefor |
| HRP20030840A2 (en) | 2001-05-17 | 2005-08-31 | Applied Research Systems Ars Holding N.V. | Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| AU2002312566A1 (en) | 2001-07-09 | 2003-01-29 | Elan Pharmaceuticals, Inc. | Methods of inhibiting amyloid toxicity |
| US7205398B2 (en) | 2002-05-24 | 2007-04-17 | Schering-Plough Animal Health Corporation | Eta-1 gene and methods for use |
| EP1637159A4 (en) * | 2003-05-23 | 2009-01-21 | Immuno Biological Lab Co Ltd | IMMUNOCOMPETENT CELL ACTIVATION INHIBITOR AND USE THEREOF |
| WO2008086449A2 (en) | 2007-01-09 | 2008-07-17 | Oregon Health & Science University | Synthetic osteopontin peptides and methods of use |
| JP2010520181A (ja) | 2007-03-02 | 2010-06-10 | ナショナル・ユニバーシティ・オブ・アイルランド・ゴルウェイ | 心血管疾患の予測および治療のためのオステオポンチン |
| WO2008131094A1 (en) | 2007-04-17 | 2008-10-30 | Pfizer Inc. | Method for controlling glucose uptake and insulin sensitivity |
| CN101293916A (zh) | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途 |
| RU2010121967A (ru) * | 2007-10-31 | 2011-12-10 | Медиммун, Ллк (Us) | Белковые каркасные структуры |
| CN101215324B (zh) * | 2007-12-26 | 2010-11-24 | 吉林大学 | 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用 |
| WO2011058182A1 (en) * | 2009-11-13 | 2011-05-19 | National University Of Ireland, Galway | Osteopontin-conditioned medium for the treatment of vascular diseases |
| GB2493540A (en) * | 2011-08-10 | 2013-02-13 | Follicum Ab | Agents for stimulating hair growth in mammals |
| EP2875134A1 (en) | 2012-07-20 | 2015-05-27 | Arla Foods amba | Osteopontin peptide fragments for use in suppression or prevention of tumor growth |
| GB201406989D0 (en) * | 2014-04-17 | 2014-06-04 | Follicum Ab | Novel treatments |
| CA3021994A1 (en) | 2016-05-06 | 2017-11-09 | Brett P. Monia | Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof |
-
2018
- 2018-05-04 ES ES18721806T patent/ES2857749T3/es active Active
- 2018-05-04 SG SG11201908513R patent/SG11201908513RA/en unknown
- 2018-05-04 CA CA3061935A patent/CA3061935A1/en active Pending
- 2018-05-04 AU AU2018262805A patent/AU2018262805B2/en active Active
- 2018-05-04 IL IL270199A patent/IL270199B2/en unknown
- 2018-05-04 KR KR1020197027946A patent/KR102700014B1/ko active Active
- 2018-05-04 PL PL18721806T patent/PL3618845T3/pl unknown
- 2018-05-04 EA EA201992562A patent/EA201992562A1/ru unknown
- 2018-05-04 MX MX2019013096A patent/MX2019013096A/es unknown
- 2018-05-04 JP JP2019555219A patent/JP2020518556A/ja active Pending
- 2018-05-04 BR BR112019021886-6A patent/BR112019021886A2/pt unknown
- 2018-05-04 DK DK18721806.0T patent/DK3618845T3/da active
- 2018-05-04 WO PCT/EP2018/061547 patent/WO2018202870A1/en not_active Ceased
- 2018-05-04 CN CN201880026723.5A patent/CN110545834B/zh active Active
- 2018-05-04 EP EP18721806.0A patent/EP3618845B1/en active Active
-
2019
- 2019-09-06 ZA ZA2019/05891A patent/ZA201905891B/en unknown
- 2019-10-29 US US16/666,960 patent/US10815283B2/en active Active
-
2020
- 2020-09-16 US US17/022,526 patent/US20210009648A1/en not_active Abandoned
-
2023
- 2023-03-28 JP JP2023051477A patent/JP2023082076A/ja not_active Ceased
-
2025
- 2025-03-10 JP JP2025037548A patent/JP2025090703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518556A5 (enExample) | ||
| Iorga et al. | Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect | |
| Gupta | Glucagon-like peptide-1 analogues: an overview | |
| Madsen et al. | Structure− activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness | |
| JP3149958B2 (ja) | Ｇｌｐ―１誘導体 | |
| Okerson et al. | The cardiovascular effects of GLP‐1 receptor agonists | |
| TW201247702A (en) | Use of acylated glucagon analogues | |
| Kim et al. | The nonglycemic actions of dipeptidyl peptidase‐4 inhibitors | |
| CN106459170B (zh) | 衍生自毒蜥外泌肽-4的glp-1/胰高血糖素受体双重激动剂 | |
| Choe et al. | Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists | |
| Tomlinson et al. | An overview of new GLP-1 receptor agonists for type 2 diabetes | |
| TW201625672A (zh) | 升糖素及ｇｌｐ－１受體之共促效劑 | |
| Lotfy et al. | Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus | |
| CN104736558A (zh) | 用于治疗代谢综合征的融合蛋白 | |
| Gallwitz | GLP-1 agonists and dipeptidyl-peptidase IV inhibitors | |
| CN106279400A (zh) | P8降糖肽的设计及其用途 | |
| Li et al. | Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2 | |
| WO2002066062A2 (en) | Enhancement of glp-2 activity | |
| Wang et al. | The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives | |
| Heo et al. | Glucagon-like peptide-1 and its cardiovascular effects | |
| Frías | An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program | |
| Camaya et al. | How do parasitic worms prevent diabetes? An exploration of their influence on macrophage and β-cell crosstalk | |
| Gaggini et al. | Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology | |
| Gu et al. | The therapeutic potential of the adiponectin pathway | |
| Li et al. | Self-assembling peptides improve the stability of glucagon-like peptide-1 by forming a stable and sustained complex |